Optimizing iPSC derived cell therapy development for allogeneic and therapeutic applications @Labroots
Optimizing iPSC derived cell therapy development for allogeneic and therapeutic applications  @Labroots
Uploaded December 2025 | Updated November 2026, 6 hours ago
Presented By: Dr. Omar Farah



Speaker Biography: Dr Farah received his doctorate from McGill University in Canada, where he studied early embryo lineage specification and development of the female reproductive tract needed for proper embryo-uterine crosstalk. Omar continued his postdoctoral work at the University of California, San Diego, where he focused on using stem cell-based models to study extra-embryonic lineage specification, trophoblast differentiation, and placental development.

Currently, Dr Farah is working at Thermo Fisher, managing a team of regenerative medicine field application scientists supporting stem cell, neurobiology, cell and gene therapy workflows.



Webinar: Optimizing iPSC-derived cell therapy development for allogeneic and therapeutic applications



Webinar Abstract: With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and differentiation, and to optimize iPSC-derived cell therapy production workflows.

Dr. Farah will discuss strategies to address a range of issues and bottlenecks in iPSC-derived cell therapy development. Using iPSC-derived CAR-NK (iNK) cells as an example, he will explore solutions for successful iPSC culturing and scale-up before sharing an optimized multi-step protocol to differentiate iPSCs to HSPCs to NK cells.



Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-gene-therapy-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-gene-therapy-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 10/15/2026): (labroots.com/virtual-event/cell-gene-therapy-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link



Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc
Optimizing iPSC derived cell therapy development for allogeneic and therapeutic applicationsUltrasensitive, High-Throughput nanoHDX-MS for Insights into Protein Dynamics and InteractionsD Dimer: A routine assay with unique challengesIdentifying blood-based signatures of Traumatic Brain Injury using high sensitivity, multiplexed...Navigating Patient Testing Pitfalls: Lab Leaders Perspectives on Turning Practice Gaps into...Burn Fat, Not Muscle: Gene Silencing to Reprogram Fat, Boost Energy Expenditure, and Treat ObesityDigital pathology and Artificial Intelligence application in Hematological Diagnostics: Game...Revolutionizing Autoimmune Diagnostics: Dr. Veena Joy on CAR-T & Womens HealthKnow Thy Sample - 5 methods to quantify your protein and when to use themAnalysis of microplastics and other anthropogenic particles in different matricesMAFG A key regulator in melanoma progression and a potential therapeutic targetUsing algorithms and AI to make genomic data work better for patients
Labroots |

Optimizing iPSC derived cell therapy development for allogeneic and therapeutic applications

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER